HomeAveraAvera Names Myles Greenberg, MD, as CEO of Alucent Medical

Avera Names Myles Greenberg, MD, as CEO of Alucent Medical


“NVS Therapy has the potential to dramatically improve the care of patients suffering from debilitating peripheral vascular disease, and I look forward to being a part of the team advancing this groundbreaking technology into patient treatment,” Dr. Greenberg said.

Myles D. Greenberg, MD, was named President and CEO of Alucent Medical, Inc., a new company licensed to develop a novel drug/device combination therapy for the treatment of peripheral vascular disease (PVD). The treatment, Natural Vascular Scaffolding (NVS)TM, has recently gained FDA approval to move forward with Phase 1 human clinical trials.

Alucent is owned by the research and development arm of Avera Health, based in Sioux Falls, S.D.

NVS combines percutaneous balloon angioplasty (PTA) with a novel drug that builds natural scaffolding to keep the vessel open, potentially replacing the need for a stent. Current therapies such as PTA and implanted stents can result in recurrence of the vascular lesion, requiring the need for retreatment. Avera scientists developed this product under the leadership of Ron Utecht, PhD.

“NVS Therapy has the potential to dramatically improve the care of patients suffering from debilitating peripheral vascular disease, and I look forward to being a part of the team advancing this groundbreaking technology into patient treatment,” Dr. Greenberg said.

Dr. Greenberg brings to Alucent Medical, Inc. extensive experience in life-sciences related business and new product development, having served as a partner in early-stage health care venture capital firms HealthInvest Equity Partners and CHL Medical Partners based in Stamford, Conn., and as an active director of many companies developing novel medical devices, biopharmaceuticals and health care technologies.

Prior to his career in venture capital, Dr. Greenberg was an academic emergency physician and hospital administrator at Beth Israel Deaconess Medical Center/Harvard Medical School in Boston, Mass. He holds a bachelor of applied science degree from the University of Pennsylvania School of Engineering and Applied Science; doctor of medicine degree from Yale University School of Medicine; and master of business administration from Harvard University Graduate School of Business Administration.

“Dr. Greenberg’s experience and knowledge of the biotechnology landscape will guide us through the crucial next steps of development,” said Dave Kapaska, DO, Regional President and CEO of Avera McKennan Hospital & University Health Center. “Avera has been supporting and investing in the research and development of this product since its inception, and with his leadership, we can realize its potential.”

“With his years of experience helping early-stage companies develop new medical technologies, Dr. Greenberg is the right person to move Alucent forward toward successful clinical trials and eventual marketing,” said James Corbett, Chairman of the Alucent Board of Directors. “We look forward to the successful development of this important new therapy for patients.”

About Alucent Medical, Inc.

Alucent Medical Inc. is a privately held biotechnology company headquartered in Salt Lake City, Utah. Alucent Medical was founded by Avera Health to develop and market Natural Vascular Scaffolding (NVS), a novel combination drug-device product for the treatment of patients suffering from peripheral vascular disease. Alucent Medical is currently conducting U.S. phase 1 human clinical trials. Visit alucentmedical.com for more information.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy